

## Newsletter #2 - October 2023

Dear Investigators,

Time for an update regarding the CASES trial!

Since the first patient was included on the 5th of July, several sites have been activated and have started including patients. In the first week of September the 10th patient was included, which means that we are officially in the double digits! (Look at the graphs below to see which centers have included patients).

Recently, we submitted the first protocol amendment to the Dutch and Belgian Ethical committees. The amendment has been approved in the Netherlands and Belgium.

Here is a short overview of the most important changes:

- Protocol changes
  - 'Eptifibatide' can be used as escape medication in case of in stent thrombosis (in addition to tirofiban)
  - The 'React' aspiration catheter from Medtronic has been added to the list of accepted EVT devices.
  - $\circ~$  We included occurence of subarachnoid hemorrhage on brain CT day 1 as a safety outcome parameter.
- Addition of Noordwest Ziekenhuisgroep Alkmaar as participating center.

We hope that all local PI's (especially in the Netherlands) will prioritize the local approval and site initiation to be able to start with the inclusion of patients as soon as possible.

On behalf of the CASES coordinating team, have a great week!


## Site initiations:

- Elizabeth TweeSteden 2/10/2023
- Isala Klinieken, Zwolle 5/10/2023
- Rijnstate Ziekenhuis 9/10/2023
- ASZ 16/10/2023
- MST 19/10/2023
- Catharina 24/10/2023


## Active sites:

- UZ Leuven
- AZ Groeninge Kortrijk
- AZ Sint-Jan Brugge
- ULB Erasme
- CHC Liège
- UCL-Saint Luc
- CHU Charleroi
- UMC Groningen
- Amsterdam UMC
- Haaglanden MC

## **Total inclusions: 17**



The progress of the trial can be followed via the CASES website: <u>https://cases-trial.eu/progress-of-the-trial.html</u>



Documents such as the study protocol, information letters/informed consent forms and paper CRF worksheets can be found on the CASES website: www.cases-trial.eu/

If you have any questions don't hesitate to contact us via <u>cases</u>-<u>trial@umcg.nl</u> or +31 6 5272 4593.

